<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=7912114" created="04/03/2006" creator="Junko Matsuura"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>7912114</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term id="T1" lex="pentoxifylline" sem="Organic_compound_other">Pentoxifylline</term> for the treatment of infection with <term id="T2" lex="human_immunodeficiency_virus" sem="Virus">human immunodeficiency virus</term>.</sentence>
<event KT="Other" id="E1">
<type class="Initiation_of_viral_infection"/>
<theme idref="T2"/>
<clue>Pentoxifylline for the treatment of <clueType>infection</clueType> <linkTheme>with</linkTheme> human immunodeficiency virus.</clue>
</event>
<event KT="Other" id="E2">
<type class="Artificial_process"/>
<theme idref="T1"/>
<clue>Pentoxifylline <linkCause>for</linkCause> the <clueType>treatment</clueType> of infection with human immunodeficiency virus.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2"><term id="A1" sem="Protein_molecule">Cytokine</term> dysregulation in <term id="T3" lex="human_immunodeficiency_virus_type_1_(HIV-1)_infection" sem="Other"><term id="T4" lex="human_immunodeficiency_virus_type_1" sem="Virus">human immunodeficiency virus type 1</term> (<term id="T5" lex="HIV-1" sem="Virus">HIV-1</term>) infection</term> has been documented in numerous studies and has been cited as an important component in the pathogenesis of this <term id="T6" lex="retroviral_infection" sem="Other">retroviral infection</term>.</sentence>
<event KT="Other" id="E3">
<type class="Initiation_of_viral_infection"/>
<theme idref="T5"/>
<clue>Cytokine dysregulation in human immunodeficiency virus type 1 (HIV-1) <clueType>infection</clueType> has been documented in numerous studies and has been cited as an important component in the pathogenesis of this retroviral infection.</clue>
</event>
<event KT="Analysis" Polarity="Negative" Source="Other" id="E4">
<type class="Regulation"/>
<theme idref="A1"/>
<cause idref="E3"/>
<clue>Cytokine <clueType><cluePolarity>dys</cluePolarity>regulation</clueType> <linkCause>in</linkCause> human immunodeficiency virus type 1 (HIV-1) infection has been <clueKT>documented</clueKT> <clueSource>in numerous studies</clueSource> and has been cited as an important component in the pathogenesis of this retroviral infection.</clue>
</event>
<event KT="Other" id="E105">
<type/>
<cause idref="E3"/>
<clue>Cytokine dysregulation in human immunodeficiency virus type 1 (HIV-1) infection has been documented in numerous studies and has been cited as an important component in the <clueType>pathogenesis</clueType> <linkCause>of</linkCause> <corefTheme>this retroviral infection</corefTheme>.</clue>
<comment>SOO</comment></event>
<event KT="Analysis" Source="Other" id="E5">
<type class="Correlation"/>
<theme idref="E4"/>
<theme idref="E105"/>
<clue>Cytokine dysregulation in human immunodeficiency virus type 1 (HIV-1) infection has been documented in numerous studies and <clueSource>has been</clueSource> <clueKT>cited</clueKT> as an <clueType>important component</clueType> <linkTheme>in</linkTheme> the pathogenesis of this retroviral infection.</clue>
</event>
<sentence id="S3">Pharmacological modification of <term id="T7" lex="cytokine_dysregulation" sem="Other"><term id="T8" lex="cytokine" sem="Protein_family_or_group">cytokine</term> dysregulation</term>, therefore, has been suggested as a <term id="T9" lex="therapeutic_modality" sem="Other">therapeutic modality</term> for <term id="T10" lex="HIV-1_infection" sem="Other"><term id="T11" lex="HIV-1" sem="Virus">HIV-1</term> infection</term>.</sentence>
<event KT="Other" id="E51">
<type class="Initiation_of_viral_infection"/>
<theme idref="T11"/>
<clue>Pharmacological modification of cytokine dysregulation, therefore, has been suggested as a therapeutic modality for HIV-1 <clueType>infection</clueType>.</clue>
</event>
<event KT="Other" id="E52">
<type class="Regulation"/>
<theme idref="T8"/>
<clue>Pharmacological modification of cytokine <clueType>dysregulation</clueType>, therefore, has been suggested as a therapeutic modality for HIV-1 infection.</clue>
</event>
<event CL="L2" KT="Analysis" Source="Other" id="E53">
<type class="Regulation"/>
<theme idref="E52"/>
<clue><clueType>Pharmacological modification</clueType> <linkTheme>of</linkTheme> cytokine dysregulation, <clueKT>therefore</clueKT>, <clueSource>has been</clueSource> <clueCL>suggested</clueCL> as a therapeutic modality for HIV-1 infection.</clue>
</event>
<sentence id="S4">Dr. Dezube of Beth Israel Hospital (Boston) concisely reviews the state of our knowledge regarding the effects of <term id="T12" lex="pentoxifylline" sem="Organic_compound_other">pentoxifylline</term> on expression of <term id="T13" lex="tumor_necrosis_factor-alpha" sem="Protein_molecule">tumor necrosis factor-alpha</term>, a <term id="T14" lex="cytokine" sem="Protein_family_or_group">cytokine</term> known to influence <term id="T15" lex="HIV-1_replication" sem="Other"><term id="T16" lex="HIV-1" sem="Virus">HIV-1</term> replication</term> and to play a possible role in the <term id="A5" sem="Other"><term id="A4" sem="Other">clinical manifestations</term> of advanced infection with this virus</term>.</sentence>
<event KT="Other" id="E8">
<type class="Gene_expression"/>
<theme idref="T13"/>
<clue>Dr. Dezube of Beth Israel Hospital (Boston) concisely reviews the state of our knowledge regarding the effects of pentoxifylline on <clueType>expression</clueType> <linkTheme>of</linkTheme> tumor necrosis factor-alpha, a cytokine known to influence HIV-1 replication and to play a possible role in the clinical manifestations of advanced infection with this virus.</clue>
</event>
<event KT="Analysis" id="E9">
<type class="Regulation"/>
<theme idref="E8"/>
<cause idref="T12"/>
<clue>Dr. Dezube of Beth Israel Hospital (Boston) concisely <clueKT>reviews</clueKT> the state of our knowledge regarding the <clueType>effects</clueType> <linkCause>of</linkCause> pentoxifylline <linkTheme>on</linkTheme> expression of tumor necrosis factor-alpha, a cytokine known to influence HIV-1 replication and to play a possible role in the clinical manifestations of advanced infection with this virus.</clue>
</event>
<event KT="Other" id="E64">
<type class="Viral_life_cycle"/>
<theme idref="T16"/>
<clue>Dr. Dezube of Beth Israel Hospital (Boston) concisely reviews the state of our knowledge regarding the effects of pentoxifylline on expression of tumor necrosis factor-alpha, a cytokine known to influence HIV-1 <clueType>replication</clueType> and to play a possible role in the clinical manifestations of advanced infection with this virus.</clue>
</event>
<event KT="Fact" id="E65">
<type class="Regulation"/>
<theme idref="E64"/>
<cause idref="T13"/>
<clue>Dr. Dezube of Beth Israel Hospital (Boston) concisely reviews the state of our knowledge regarding the effects of pentoxifylline on expression of tumor necrosis factor-alpha, a cytokine <clueKT>known</clueKT> to <clueType>influence</clueType> HIV-1 replication and to play a possible role in the clinical manifestations of advanced infection with this virus.</clue>
</event>
<event KT="Other" id="E66">
<type class="Initiation_of_viral_infection"/>
<theme idref="T16"/>
<clue>Dr. Dezube of Beth Israel Hospital (Boston) concisely reviews the state of our knowledge regarding the effects of pentoxifylline on expression of tumor necrosis factor-alpha, a cytokine known to influence HIV-1 replication and to play a possible role in the clinical manifestations of <clueType>advanced infection</clueType> <linkTheme>with</linkTheme> <corefTheme>this virus</corefTheme>.</clue>
</event>
<event CL="L1" KT="Analysis" id="E67">
<type class="Regulation"/>
<theme idref="A5"/>
<cause idref="T13"/>
<clue>Dr. Dezube of Beth Israel Hospital (Boston) concisely reviews the state of our knowledge regarding the effects of pentoxifylline on expression of tumor necrosis factor-alpha, a cytokine known to influence HIV-1 replication and to <clueType>play</clueType> a <clueKT><clueCL>possible</clueCL></clueKT> <clueType>role</clueType> <linkTheme>in</linkTheme> the clinical manifestations of advanced infection with this virus.</clue>
<comment>TPS: A5</comment></event>
<sentence id="S5"><term id="T17" lex="pentoxifylline" sem="Organic_compound_other">Pentoxifylline</term>, a <term id="T18" lex="trisubstituted_xanthine_derivative" sem="Organic_compound_other">trisubstituted xanthine derivative</term>, has been used to decrease <term id="T19" lex="blood_viscosity" sem="Other">blood viscosity</term> and is reasonably well tolerated by most recipients of the drug.</sentence>
<event id="E14">
<type class="Negative_regulation"/>
<theme idref="T19"/>
<cause idref="T17"/>
<clue>Pentoxifylline, a trisubstituted xanthine derivative, has been used to <clueType>decrease</clueType> blood viscosity and is reasonably well tolerated by most recipients of the drug.</clue>
</event>
<sentence id="S6">Results of preliminary studies, many of which were conducted by <term id="T20" lex="Dr._Dezube" sem="Multicellular_organism_natural">Dr. Dezube</term>, suggest that use of this agent in combination with <term id="A6" sem="Organic_compound_other">antiretroviral compounds</term> may prove useful in the treatment of <term id="T21" lex="patient" sem="Multicellular_organism_natural">patients</term> with <term id="T22" lex="HIV-1" sem="Virus">HIV-1</term> infection.</sentence>
<event KT="Other" id="E15">
<type class="Initiation_of_viral_infection"/>
<theme idref="T22"/>
<clue>Results of preliminary studies, many of which were conducted by Dr. Dezube, suggest that use of this agent in combination with antiretroviral compounds may prove useful in the treatment of patients with HIV-1 <clueType>infection</clueType>.</clue>
</event>
<event CL="L2" KT="Analysis" id="E68">
<type class="Artificial_process"/>
<theme idref="T17"/>
<theme idref="A6"/>
<clue>Results of preliminary studies, many of which were conducted by Dr. Dezube, <clueKT><clueCL>suggest</clueCL></clueKT> that <clueType>use</clueType> <linkTheme>of</linkTheme> <corefTheme idref1="T17">this agent</corefTheme> <linkTheme>in combination with</linkTheme> antiretroviral compounds may prove useful in the treatment of patients with HIV-1 infection.</clue>
</event>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
